Author of

• 28120

  +

  Poster Session (ID 8)

  • Event: ACLC 2018
  • Type: Poster Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall

  • 28151

    +

    P058 - Effects of Neoadjuvant Chemotherapy on the Expression (ID 82)

    00:00 - 00:00  |  Author(s): W. Sun
    • Abstract

    Background:
    Immune checkpoints PD-1 and its ligand PD-L1, PD-L2 pathways can mediate negative synergistic stimulation signals. Immunotherapy combined with chemotherapy can increase the objective response rate of cancer patients. This study aims to analyze the changes of PD-L1, PD-L2 in lung cancer tissues and the changes of TILs surrounding the tumor before and after neoadjuvant chemotherapy, in order to provide a theoretical basis for relevant clinical studies.
    
    
    Method:
    Tumor samples were obtained from 26 patients who confirmed primary lung cancer before and after NAC in the First Hospital of Jilin University. The expression of PD-L1, PD-L2 in lung cancer specimens and the TILs around the tumor were assessed by IHC. 5%, 10%, 20%, 30%, 50% expression thresholds were used to define PD-L1, PD-L2 positive status, respectively. We analyze the changes of PD-L1 and PD-L2 in lung cancer tissues before and after NAC, the correlation between the changes of PD-L1 in lung cancer tissues and tumor shrink rate, the interval from the end of NAC to operation, pathological type, gender and smoking status. Of 16 patients, the changes of TILs around the tumor before and after NAC were also evaluated. P<0.05 was considered statistically significant.
    
    
    Results:
    1. When using 5%, 10%, and 20% as expression threshold, 65.4%, 53.8%, and 42.3% were found to be PD-L1 positive prior to NAC, and 92.3%, 80.8%, 69.2% expressed positively after NAC, PD-L1 was up-regulated after NAC (P=0.008, P=0.016, P=0.016 ), however, there were no obviously statistical significance about the expression of PD-L1 when using 30%, 50% expression threshold (P?0.05 ). 2. The expression of PD-L2 were not show any statistical significance before and after NAC?P?0.05 ) . 3. Of 16 patients, the expression of CD4+, CD8+, and CD28+ lymphocytes increased after NAC compared with that before NAC (P=0.014, P=0.038, P=0.021), whereas the change of CD56+ lymphocytes was not statistical significant (P> 0.05). 4. There were no significant difference between the changes of PD-L1 and tumor shrink rate, interval from the end of NAC to operation, pathological type, gender and smoking status (P?0.05 ) .
    
    
    Conclusion:
    1. The expression of PD-L1 in lung cancer tissues were increased after NAC when the expression thresholds were 5%, 10%, and 20%. 2. The expression of CD4+, CD8+ and CD28+ lymphocytes were increased after NAC. 3. No correlation exists between the variation of PD-L1 and tumor shrink rate, interval from the end of NAC to operation, pathological type, gender and smoking status.